StockWatch
·

Apimeds Pharmaceuticals US, Inc.

Ticker: 1894525

P/L Snapshot

Q3 FY26 · consolidated

vs Q2 FY26
Revenue
2.90
+935.7%
Expenditure
0.87
-95.7%
Net Profit
33.65
+266.8%
OPM %
70.03%

Shareholding

Pattern breakdown

P/L Trends

(in millions)

RevenueExpenditureNet Profit
-26.63-9.946.7423.4240.11Q2 FY26Q3 FY26
Price Chart
Latest News

Corporate Events

Board MeetingAPUS
2026
29Sep

Board Meeting

Erick Frim resigned as Interim Chief Financial Officer and E…

SEC Filing ↗
Board MeetingAPUS
2026
10Sep

Board Meeting

The Board composition has been restructured following an ame…

SEC Filing ↗
Board MeetingAPUS
2026
5Aug

Board Meeting

Appointment of Dr. Christopher Kim as Chief Scientific Offic…

SEC Filing ↗
Stock SplitAPUS
2026
24Jul

1:10

SEC Filing ↗
Stock SplitAPUS
2026
24Jul

1:10

SEC Filing ↗
Board MeetingAPUS
2026
4May

Board Meeting

Appointment of Sungjoon Chae as Co-Chief Executive Officer …

SEC Filing ↗
Board MeetingAPUS
2026
24Apr

Board Meeting

Apimeds Pharmaceuticals US, Inc. entered into a Confidential…

SEC Filing ↗
Board MeetingAPUS
2026
20Mar

Board Meeting

Clarification that previously reported purported removals of…

SEC Filing ↗